VitaSignalClinical IntelligenceInteractive Product Tour
Perspective

VitaSignal Interactive Product Tour

Turn a proposed clinical AI use case into a decision your healthcare organization can defend.

See how VitaSignal organizes intended use, data readiness, evidence, risk, controls, and unresolved questions into a versioned Governance Decision Package.

Explore a decision path

Product tour using generated data. No PHI.

Public worked example of the Clinical AI Documentation Readiness Evaluation.

Clinical AI Documentation Readiness Evaluation

One platform, two working surfaces, one versioned package.

The Governance Review Workspace holds the decision record. The Data Pathway Readiness Workspace establishes what the local documentation pathway can support. They are working surfaces within VitaSignal, not separate products.

  1. 01Scope the intended use
  2. 02Assess data readiness
  3. 03Review the evidence
  4. 04Connect risks to controls
  5. 05Form a recommendation
  6. 06Produce the decision package

Product tour scenarios

Explore a decision path

4 scenarios
Decision path A · Step 1 of 6

Scope the intended use

Working surface: Governance Review Workspace

Recommendation: Modify
Bounded intended-use question

Does an institutionally external retrospective confirmation of added discrimination support progression, given the adverse calibration and utility findings recorded in the same evaluation?

Read-only review of a documentation-derived component signal confirmed on an institutionally external retrospective record.

Permitted use

Retrospective component review, limitation review, and redesign of the evidence plan.

Prohibited use

Clinical utility, patient benefit, generalizability, deployment readiness, or complete-product validation claims.

Required evidenceAll requirements are checked at the gate
  • Frozen comparator and cutoff
  • Calibration and utility reporting
  • Missingness sensitivity
  • Demographic, hospital, and vendor fields
A · Local Readiness Review

Evidence status

Generated examples, explicit boundaries.

Examples use generated data and do not establish clinical effectiveness. Retrospective or approved read-only review comes first; later observational work requires prespecified evidence gates and separate written authorization.